Can targeted metabolomics predict depression recovery? Results from the CO-MED trial - PubMed (original) (raw)
Randomized Controlled Trial
Can targeted metabolomics predict depression recovery? Results from the CO-MED trial
Andrew H Czysz et al. Transl Psychiatry. 2019.
Abstract
Metabolomics is a developing and promising tool for exploring molecular pathways underlying symptoms of depression and predicting depression recovery. The AbsoluteIDQ™ p180 kit was used to investigate whether plasma metabolites (sphingomyelins, lysophosphatidylcholines, phosphatidylcholines, and acylcarnitines) from a subset of participants in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial could act as predictors or biologic correlates of depression recovery. Participants in this trial were assigned to one of three pharmacological treatment arms: escitalopram monotherapy, bupropion-escitalopram combination, or venlafaxine-mirtazapine combination. Plasma was collected at baseline in 159 participants and again 12 weeks later at study exit in 83 of these participants. Metabolite concentrations were measured and combined with clinical and sociodemographic variables using the hierarchical lasso to simultaneously model whether specific metabolites are particularly informative of depressive recovery. Increased baseline concentrations of phosphatidylcholine C38:1 showed poorer outcome based on change in the Quick Inventory of Depressive Symptoms (QIDS). In contrast, an increased ratio of hydroxylated sphingomyelins relative to non-hydroxylated sphingomyelins at baseline and a change from baseline to exit suggested a better reduction of symptoms as measured by QIDS score. All metabolite-based models performed superior to models only using clinical and sociodemographic variables, suggesting that metabolomics may be a valuable tool for predicting antidepressant outcomes.
Conflict of interest statement
MHT has served as a consultant or on the advisory board for Alkeremes Inc., Akili Interactive, Navitor, Otsuka America Pharmaceutical Inc., Allergan Pharmaceuticals, Lundbeck Research USA, Medscape, MSI Methylation Sciences – Pamlab Inc., One Carbon Therapeutics, Takeda Global Research, Avanir Pharmaceuticals, Johnson & Johnson Pharmaceutical Research & Development. He has received grants from the National Institute of Mental Health (NIMH), National Institute of Drug Abuse (NIDA), National Center for Advancing Translational Sciences (NCATS), Cancer Prevention and Research Institute of Texas (CPRIT), the Patient-Centered Outcomes Research Institute (PCORI), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Agency for Healthcare Research and Quality (AHRQ), Johnson & Johnson. He has received honoraria from the American Psychiatric Association. The authors declare that they have no conflict of interest.
Figures
Fig. 1
Sub-setting of the CO-MED trial based on baseline and exit plasma cohorts (a) and model generation workflow (b)
Similar articles
- Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity.
Jha MK, Minhajuddin A, South C, Rush AJ, Trivedi MH. Jha MK, et al. Am J Psychiatry. 2019 May 1;176(5):358-366. doi: 10.1176/appi.ajp.2018.18030355. Epub 2019 Mar 29. Am J Psychiatry. 2019. PMID: 30922100 - Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial.
Jha MK, Malchow AL, Grannemann BD, Rush AJ, Trivedi MH. Jha MK, et al. Neuropsychopharmacology. 2018 Oct;43(11):2197-2203. doi: 10.1038/s41386-018-0180-z. Epub 2018 Aug 15. Neuropsychopharmacology. 2018. PMID: 30135556 Free PMC article. Clinical Trial. - Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
Zisook S, Lesser IM, Lebowitz B, Rush AJ, Kallenberg G, Wisniewski SR, Nierenberg AA, Fava M, Luther JF, Morris DW, Trivedi MH. Zisook S, et al. J Clin Psychiatry. 2011 Oct;72(10):1322-32. doi: 10.4088/JCP.10m06724. J Clin Psychiatry. 2011. PMID: 22075098 Clinical Trial. - Novel Augmentation Strategies in Major Depression.
Martiny K. Martiny K. Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review. - Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks.
Gadad BS, Jha MK, Czysz A, Furman JL, Mayes TL, Emslie MP, Trivedi MH. Gadad BS, et al. J Affect Disord. 2018 Jun;233:3-14. doi: 10.1016/j.jad.2017.07.001. Epub 2017 Jul 5. J Affect Disord. 2018. PMID: 28709695 Free PMC article. Review.
Cited by
- Acylcarnitines are associated with lower depressive symptomatology in a mainland puerto rican cohort.
Palacios N, Bhupathiraju SN, Kelly RS, Lee JS, Ordovas JM, Tucker KL. Palacios N, et al. Metabolomics. 2024 Jul 27;20(4):85. doi: 10.1007/s11306-024-02116-z. Metabolomics. 2024. PMID: 39066829 - Integrated Module of Multidimensional Omics for Peripheral Biomarkers (iMORE) in patients with major depressive disorder: rationale and design of a prospective multicentre cohort study.
Zheng Y, Zhang L, He S, Xie Z, Zhang J, Ge C, Sun G, Huang J, Li H. Zheng Y, et al. BMJ Open. 2022 Nov 23;12(11):e067447. doi: 10.1136/bmjopen-2022-067447. BMJ Open. 2022. PMID: 36418119 Free PMC article. - Network science approach elucidates integrative genomic-metabolomic signature of antidepressant response and lifetime history of attempted suicide in adults with major depressive disorder.
Grant CW, Wilton AR, Kaddurah-Daouk R, Skime M, Biernacka J, Mayes T, Carmody T, Wang L, Lazaridis K, Weinshilboum R, Bobo WV, Trivedi MH, Croarkin PE, Athreya AP. Grant CW, et al. Front Pharmacol. 2022 Oct 3;13:984383. doi: 10.3389/fphar.2022.984383. eCollection 2022. Front Pharmacol. 2022. PMID: 36263124 Free PMC article. - Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study.
Guan X, Xu J, Xiu M, Li X, Liu H, Wu F. Guan X, et al. CNS Neurosci Ther. 2022 Oct;28(10):1539-1546. doi: 10.1111/cns.13895. Epub 2022 Jun 29. CNS Neurosci Ther. 2022. PMID: 35769008 Free PMC article. - Metabolomics of Major Depressive Disorder: A Systematic Review of Clinical Studies.
F Guerreiro Costa LN, Carneiro BA, Alves GS, Lins Silva DH, Faria Guimaraes D, Souza LS, Bandeira ID, Beanes G, Miranda Scippa A, Quarantini LC. F Guerreiro Costa LN, et al. Cureus. 2022 Mar 9;14(3):e23009. doi: 10.7759/cureus.23009. eCollection 2022 Mar. Cureus. 2022. PMID: 35415046 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical